11 Early stage research fellowships: STACCATO Marie Skłodowska-Curie EID

We are pleased to advertise 11 Early Stage Researcher Positions (Early Stage Researchers [ESRs]) within the recently granted European Industrial Doctorate project STACCATOEuropean Industrial Doctorate for enhancing upstream biopharmaceutical manufacturing process development through single cell analysis.

STACCATO has been specifically designed to strengthen Europe’s innovation capacity and leadership in biopharmaceutical manufacturing science by providing world-class intersectoral training to 11 Early Stage Researchers (ESRs) and creating and applying pioneering manufacturing process development approaches for biopharmaceuticals. The STACCATO partners are united by the shared vision to utilise high-resolution data captured simultaneously from thousands of single cells to develop new manufacturing methods for biopharmaceuticals.

All recruited researchers will spend at least 18 of their 36 months on the project at industry partners. The multidisciplinary and intersectoral doctoral programme is based on a modular system that addresses the individual needs of the ESRs.

More details: https://euraxess.ec.europa.eu/jobs/368955

GapSummit 2019

Broad Institute of Harvard and MIT, USA
June 16-20th 2019

GapSummit is the premier, global, intergenerational biotechnology summit that attracts world leaders and the next generation of leaders to substantively discuss pressing challenges facing the bioeconomy and catalyze innovation to address these challenges.

GapSummit competitively selects 100 Leaders of Tomorrow from around the world to attend the summit. We look for students, entrepreneurs and young professionals with a proven track record of leadership and expertise in the biotech field. GapSummit 2019 will provide Leaders of Tomorrow with an unparalleled opportunity to network with, challenge and learn from current world leaders in the biotech field. Leaders of Tomorrow will also gain a comprehensive overview of biotech trends and issues, inciting discussion about world challenges that will to be met by scientific and business innovations.

https://gapsummit.com

 

BioProNET members win innovator of the year

BioProNET members Ben Dolman and James Winterburn won the BBSRC 2018 Innovator of the Year in the Early Career researcher category.

Some information about their innovative work — partly funded by BioProNET — can be found on our case studies page http://biopronetuk.org/case-studies-of-biopronet-funding/
Scientific exchange visit boosts separation technologies collaboration
Collaborative development of glycolipid separation technology to reduce costs

Outcomes of IBSCA funding

BioProNET recently funded 7 Industrial Biotechnology Seeding Catalyst Award. These awards were designed to accelerate translational research by developing and progressing research along the technology readiness level (TRL) pathway, increasing business—academic engagement and company leverage on innovation activities, as well as generating data to support applications for larger grant funding. Below are the key aims and outcomes from each of these projects.

Download a pdf here

5th Annual Science Meeting

October 10-11th 2018
British Medical Association House, Central London

Thank you to everyone who made this meeting a huge success. Photos will be shared with members once the photos are ready.

Wednesday October 10th
9.30 Registration
10.15-10.30 Welcome, achievements and what next for BioProNET
Designing more efficient cell-expression systems chaired by Mark Smales
10.30-10.55 Kerstin Otte
 University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics
11.20-11.45 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
11.45-11.55 Andrew Peden University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells 
11.55-12.20 Nathan Lewis University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing

Building expression systems into optimised process chaired by Yvonne Genzel
13.25-13.50 Gary Finka GlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.50-14.15 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.15-14.25 Mayur Parekh Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.25-14.35 James Winterburn University of Manchester From bench to business with UKRI funding
14.35–15.00 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products

The clinic and beyond chaired by Laura Palomares
15.40-16.05 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
16.05-16.20 Simon Saxby Leaf Expression Systems Plant produced biologics – process economics
16.20-16.30 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.30-16.40 Pavlos Kotidis Imperial College London A mathematical model to describe CHO cell growth and monoclonal antibody glycosylation

18.00 Poster session
20.00 Conference dinner

Thursday October 11th
Upstream meets downstream – rapid process development chaired by Cleo Kontoravdi
9.00-9.25 Paul Dalby University College London Analysis and control of protein dynamics and stability: downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Maiken Kristiansen MedImmune Nucleic acid production for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Davide Vito University of Kent Translation engineering through the non-coding genome in CHO cells
10.35-11.00 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins

Molecular characterisation of process quality chaired by Alan Dickson
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Rosa Morra University of Manchester Classical and non-classical secretion pathways in E. coli for periplasmic and extracellular recombinant protein production
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry